Articles by Sarah Houlton - Pharmaceutical Executive

ADVERTISEMENT

Articles by Sarah Houlton

GSK Cuts Prices Again, but Generics Still Cheaper

Nov 1, 2002

After saying last year that its treatments for AIDS and malaria were as cheap as they could be, GlaxoSmithKline now claims that improved manufacturing practices and greater economies of scale allow it to reduce prices even more.

Call to Ignore Patents

UK Intellectual Property Rights Commission encourages developing countries to produce generic versions of vital medicines.
Nov 1, 2002

Patents help ensure that companies can recoup their development costs-and make profits-by selling their products without competition for a set period of time. The pharma industry has followed that model for decades.

AZ's Pipeline Problems

Oct 1, 2002

Product development glitches continue to depress share prices at AstraZeneca. Poor trial results for the company's cancer drug Iressa followed hard on the heels of bad news about its cholesterol treatment Crestor (rosuvastatin).

Toward a Bigger Biotech

Skittish investors and the need for large infusions of cash to see small biotechs through the early stage of drug development may drive a multimerger.
Oct 1, 2002

A major consolidation may be underway in the UK biotech sector. According to a report in London's Financial Times, several embattled companies specializing in cancer medicines are talking about a possible merger. Xenova, British Biotech, Antisoma, KS Biomedics, and Oxford GlycoSciences are believed to be in the early stages of discussions about merging to create a much stronger company.

Dutch Government Just Says No

Sep 1, 2002

Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance.

More Statins = Fewer Heart Attacks

Sep 1, 2002

Many more high-risk patients could benefit from statin therapy than currently receive the cholesterol-lowering drugs, according to a major UK study set up by the Medical Research Council and the British Heart Foundation.

Plants and Patents

A movement is afoot to protect the intellectual property rights of indigenous people who have used plants as medicines for generations.
Sep 1, 2002

The number of pharmaceuticals derived from nature is staggering. Many medicine cabinet staples were first isolated from natural sources-penicillin from mold, quinine from the cinchona tree, digitalis (foxglove) for heart ailments, and the list goes on.

Novo Nordisk Cancels Clinical Trials

Sep 1, 2002

Shares in Danish company Novo Nordisk took a hit after it suspended trials for one of its main pipeline candidates, the dual-acting insulin sensitizer, ragaglitazar.

Aventis Streamlines R&D

Sep 1, 2002

Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share.

ADVERTISEMENT

Click here